[
  {
    "image": "mdcg-2019-16-fig01.png",
    "pre": "• Protection against unauthorised access (sec. 17.4",
    "post": "Operation Security (sec. 14.1, 14.2, 17.1)"
  },
  {
    "image": "mdcg-2019-16-fig02.png",
    "pre": " Clinical evaluation and post-market follow-up: MDR Chapter VI and Annex XIV",
    "post": "Figure 2: Cybersecurity requirements in the MDR; the application of other relevant EU legislations, such as Cybersecurity Act, GDPR and NIS is discussed in more detail in Chapter 7"
  },
  {
    "image": "mdcg-2019-16-fig03.png",
    "pre": "effectiveness)",
    "post": "Figure 3: Cybersecurity measures may cause safety impacts"
  },
  {
    "image": "mdcg-2019-16-fig04.png",
    "pre": "Safety, security and effectiveness are critical aspects in the design of security mechanisms for in vitro diagnostic  medical  devices  and  medical  devices.  Therefore,  there  is  a  clear  requirement  that  these aspects  need  to  be  considered  by  the  manufacturers  from  an  early  stage  of  development  and manufacturing process and throughout the entire life cycle. 11",
    "post": "Figure 4 : Life cycle stages"
  },
  {
    "image": "mdcg-2019-16-fig05.png",
    "pre": "danth ateotantr la o lrat nhilnannhtr ottha cantira nendiint lifa stola",
    "post": "Figure 5: Defence in depth strategy is a key philosophy of the secure product life-cycle"
  },
  {
    "image": "mdcg-2019-16-fig06.png",
    "pre": "* Art 83-89, Annex III, XIV",
    "post": "Figure 6: Information flow in safety and security risk management for MDs"
  },
  {
    "image": "mdcg-2019-16-fig07.png",
    "pre": "Safety controls that",
    "post": ""
  }
]